spacer
home > ict > spring 2008 > the fibrotic process
PUBLICATIONS
International Clinical Trials

The Fibrotic Process

Assessing liver fibrosis in clinical trials, William Rosenberg of University College London points to the impact made by individual direct markers

Chronic liver disease is now the second most common cause of death in middle-aged men and the fifth most common cause of death in the UK overall. Out of the top five causes of death it is the only disease that is increasing. The pharmaceutical and biotechnology industries are recognising the worldwide impact of chronic viral hepatitis, alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) as well as the earning potential for new therapeutic interventions and diagnostic tests. The development of new drugs in particular is dependent on the availability of biomarkers that permit the earliest possible ‘go/no-go’ decisions and provide evidence of efficacy which ensure that drug development is rapid, efficient and safe.

The clinical impact of all chronic liver diseases (CLD) can be attributed to liver fibrosis that may progress to cirrhosis, which in turn results in the complications of portal hypertension (bleeding varices, ascites or encephalopathy), liver failure, hepatocellular cancer and death or liver transplantation. It has been recognised for decades that interventions directed at the causes of CLD can reverse the consequences of liver disease by reversing liver fibrosis. This has been established in clinical trials for the use of anti-viral agents for hepatitis B or hepatitis C, for life modifications including abstinence from alcohol and weight reduction and is integral to the investigation of drugs targeting insulin resistance that underlies NAFLD.

Now, insights into the biology of liver fibrosis have created the possibility of developing anti-fibrotic drugs that target hepatic stellate cells that are central to the production and degradation of liver matrix in fibrosis. The development of this new class of drugs targeted at the fibrotic process rather than individual causes of CLD that have broad applicability, is dependent on accurate biomarkers that are fit for purpose for use in clinical trials.

LIVER BIOPSY

For almost half a century the liver biopsy has been regarded as the standard method for assessing liver fibrosis. Careful histological examination of a biopsy by an expert pathologist remains a vital asset in the diagnosis of liver disease. However, the place of liver biopsy in the assessment of liver fibrosis is increasingly questioned. Recent research has shown that liver biopsy is associated with many problems. For the patient and funder it is painful, hazardous and costly.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor William Rosenberg founded iQur Ltd in 2003, a biotechnology company specialising in diagnostic testing for hepatitis C and other chronic liver diseases. An active academic clinician, he is Deputy Director of the Institute of Hepatology at University College London. He is an experienced Chief Investigator in many multicentre clinical trials and studies investigating diagnostic tests. As Deputy Director of UKCRN, William leads on experimental medicine, a role that aims to ensure that developments in basic science can feed through into clinically relevant research and provide new insights into basic science.
spacer
Professor William Rosenberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI MEA expert:growing domestic manufacturing is creating new opportunities for international Pharma in the Middle East

Abu Dhabi, 5th August 2019: CPhI Middle East expert Emad Shabbir, Director at EMAD Trade House, states favorable conditions and legislative regulations in Saudi Arabia are resulting in a boom of manufacturers and CMOs partnerships with international pharma companies. With the strategic cooperation between regional generic companies and multinational pharma companies, driving increased local production.
More info >>

White Papers

Quality By Design

Biopharma Group

Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >>

 
Industry Events

CPhI & P-MEC India

26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India

As the pharma industry looks increasingly towards India for high quality, low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies wanting to pick up on the latest trends and innovations the market has to offer. At CPhI & P-MEC India, you will meet the movers and shakers from India's pharma machinery, technology and ingredients industries, giving you a competitive advantage that will help grow your business.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement